Aktuelle Research
News Funktionen
Weitere Funktionen
16 May 2022
Defence Therapeutics Inc.
Original-Research: Defence Therapeutics Inc. (von GBC AG): International Investment Forum
Defence Therapeutics Inc.
Original-Research: Defence Therapeutics Inc. (von GBC AG): International Investment Forum
15 February 2022
Defence Therapeutics Inc.
Original-Research: Defence Therapeutics Inc. (von GBC AG): Kaufen
14 February 2022
Defence Therapeutics Inc.
Original-Research: Defence Therapeutics Inc. (von GBC AG): Kaufen
Defence Therapeutics Inc.
Original-Research: Defence Therapeutics Inc. (von GBC AG): BUY
10 February 2022
Defence Therapeutics Inc.
Original-Research: Defence Therapeutics Inc. (von GBC AG): BUY
25 January 2022
Defence Therapeutics Inc.
Original-Research: Defence Therapeutics Inc. (von GBC AG): –
24 January 2022
Defence Therapeutics Inc.
Original-Research: Defence Therapeutics Inc. (von GBC AG): –
7 December 2021
Defence Therapeutics Inc.
Original-Research: Defence Therapeutics Inc. (von GBC AG): Management Interview
6 December 2021
Defence Therapeutics Inc.
Original-Research: Defence Therapeutics Inc. (von GBC AG): Management Interview
Aktuelle News
News Funktionen
Weitere Funktionen
8 Juli 2024
Defence Therapeutics Inc.
DEFENCE ERHÄLT ‚NO OBJECTION LETTER’ VON DER KANADISCHEN GESUNDHEITSBEHÖRDE HEALTH CANADA FÜR SEINE PHASE I-STUDIE MIT ACCUM-002 (ACCUTOX) ALS MOLEKÜL ZUR KREBSBEKÄMPFUNG BEI PATIENTEN MIT MELANOMEN
Defence Therapeutics Inc.
DEFENCE RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA FOR PHASE I TRIAL OF ITS ACCUM-002 (ACCUTOX) AS AN ANTI-CANCER MOLECULE IN PATIENTS WITH MELANOMA
1 Juli 2024
Defence Therapeutics Inc.
ACCUTOX VON DEFENCE VERSTÄRKT DIE WIRKUNG VON IMMUNCHECKPOINTINHIBITOREN UND SCHAFFT SO SYNERGIEEFFEKTE
Defence Therapeutics Inc.
DEFENCE’S ACCUTOX BOOSTS AND SYNERGIZES WITH IMMUNE CHECKPOINT INHIBITORS
25 Juni 2024
Defence Therapeutics Inc.
DER ARM-X-IMPFSTOFF ZUR KREBSBEKÄMPFUNG VON DEFENCE HEMMT DAS WACHSTUM VON BESTEHENDEM EIERSTOCKKREBS UND FÜHRT BEI BEHANDELTEN TIEREN ZU VOLLSTÄNDIGEN REAKTIONEN
Defence Therapeutics Inc.
DEFENCE’S ARM-X ANTI-CANCER VACCINE INHIBITS GROWTH OF PRE-ESTABLISHED OVARIAN CANCER RESULTING IN COMPLETE RESPONSES IN TREATED ANIMALS